Mechanisms and Therapeutic Use of CR3 Signaling in Modulating Autoimmunity
Mechanisms and Therapeutic Use of CR3 Signaling in Modulating Autoimmunity
批准号:
7779411
负责人:
EDWARD M BEHRENS
金额:
$13.39万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-04-01 至 2014-03-31
关键词:
AddressAdherenceAdhesionsAnimal ModelAntigen PresentationAntigen-Presenting CellsAntigensApoptoticAutoantigensAutoimmune DiseasesAutoimmunityB-LymphocytesBiologyCell physiologyCellsDendritic CellsDendritic cell activationDiseaseEventExperimental Autoimmune EncephalomyelitisExposure toGoalsImmune responseImmune systemImmunizationImmunologyInjection of therapeutic agentIntegrinsInvestigationKnowledgeLCP2 geneLeadLearningLigationMacrophage-1 AntigenMediatingMitogen-Activated Protein KinasesMolecularMolecular ProbesMonoclonal AntibodiesPeptidesPhosphorylationReceptor CellResearchResearch PersonnelRheumatismRoleSignal TransductionStagingSystemic Lupus ErythematosusT-Cell ActivationT-LymphocyteTestingTherapeutic Usescytokineexperienceimmune functionin vivointerestnoveloligodendrocyte-myelin glycoproteinpathogenpreventprogramsresearch studyresponserituximabsuccess
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Complement Receptor 3 (CR3) is an apoptotic cell receptor found on dendritic cells (DCs), the most potent antigen presenting cell of the immune system. We demonstrated that activation of CR3 on DCs using a monoclonal antibody modulates DC cytokine expression and inhibits their antigen presentation capacity. The exact mechanism through which CR3 mediates its effects of DCs is still unknown, and the ability of CR3 ligated DCs to induce tolerance in vivo needs exploration.
RELEVANCE: We propose to learn the mechanisms of Complement Receptor 3 mediated suppression of dendritic cells function, and to harness this knowledge to treat autoimmunity. This proposal aims to emulate the success of the biologies, such as Rituximab or Abatacept, that were developed from the knowledge provided by basic immunology research. The experience gained in this proposal will direct efforts toward using CR3 mediated tolerance at the bedside in rheumatic diseases such as MS and SLE.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Training Program/Rheumatic Diseases
-
批准号:10614409
-
项目类别:
-
资助金额:$34.68万
-
财政年份:2020
-
负责人:EDWARD M BEHRENS
-
依托单位:
Training Program/Rheumatic Diseases
-
批准号:10375474
-
项目类别:
-
资助金额:$35.01万
-
财政年份:2020
-
负责人:EDWARD M BEHRENS
-
依托单位:
IL-33 Blockade as a Novel Therapeutic for T-cell Mediated Hypercytokinemia Syndromes
-
批准号:9175786
-
项目类别:
-
资助金额:$64.31万
-
财政年份:2016
-
负责人:EDWARD M BEHRENS
-
依托单位:
IL-33 Blockade as a Novel Therapeutic for T-cell Mediated Hypercytokinemia Syndromes
-
批准号:9291411
-
项目类别:
-
资助金额:$59.85万
-
财政年份:2016
-
负责人:EDWARD M BEHRENS
-
依托单位:
IL-33 Blockade as a Novel Therapeutic for T-cell Mediated Hypercytokinemia Syndromes
-
批准号:9926221
-
项目类别:
-
资助金额:$58.67万
-
财政年份:2016
-
负责人:EDWARD M BEHRENS
-
依托单位:
The Opposing Roles of IL-10 and IFN-gamma in Macrophage Activation Syndrome
-
批准号:8605909
-
项目类别:
-
资助金额:$41.43万
-
财政年份:2013
-
负责人:EDWARD M BEHRENS
-
依托单位:
The Opposing Roles of IL-10 and IFN-gamma in Macrophage Activation Syndrome
-
批准号:8436986
-
项目类别:
-
资助金额:$42.26万
-
财政年份:2013
-
负责人:EDWARD M BEHRENS
-
依托单位:
The Opposing Roles of IL-10 and IFN-gamma in Macrophage Activation Syndrome
-
批准号:9222038
-
项目类别:
-
资助金额:$41.6万
-
财政年份:2013
-
负责人:EDWARD M BEHRENS
-
依托单位:
Mechanisms and Therapeutic Use of CR3 Signaling in Modulating Autoimmunity
-
批准号:8442326
-
项目类别:
-
资助金额:$13.39万
-
财政年份:2009
-
负责人:EDWARD M BEHRENS
-
依托单位:
Mechanisms and Therapeutic Use of CR3 Signaling in Modulating Autoimmunity
-
批准号:8049713
-
项目类别:
-
资助金额:$13.39万
-
财政年份:2009
-
负责人:EDWARD M BEHRENS
-
依托单位:
Mechanisms and Therapeutic Use of CR3 Signaling in Modulating Autoimmunity
-
批准号:7660579
-
项目类别:
-
资助金额:$13.39万
-
财政年份:2009
-
负责人:EDWARD M BEHRENS
-
依托单位:
Mechanisms and Therapeutic Use of CR3 Signaling in Modulating Autoimmunity
-
批准号:8242838
-
项目类别:
-
资助金额:$13.39万
-
财政年份:2009
-
负责人:EDWARD M BEHRENS
-
依托单位:
Training Program/Rheumatic Diseases
-
批准号:9050629
-
项目类别:
-
资助金额:$36.17万
-
财政年份:1982
-
负责人:EDWARD M BEHRENS
-
依托单位:
海外基金